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Abstract 
Case studies have shown that low resolution electromagnetic tomography (LoRETA) 
neurofeedback is effective for many psychological disorders, but it’s effectiveness for 
individuals experiencing persistent post-concussive symptoms (PPCS) is uncertain. 
Individuals with PPCS (n = 7) received an eight-week LoRETA neurofeedback and heart rate 
variability biofeedback intervention. Change in symptoms, driving simulation performance, 
electroencephalographic z-score deviations, and heart rate variability were compared to 
PPCS (n = 9) and healthy (n = 8) control groups. Statistical analyses revealed that the 
intervention significantly reduced electroencephalographic z-score deviations (p < 0.005) 
compared to PPCS controls. Additionally, headache, nausea, and dizziness symptoms were 
reduced in the intervention group (p = 0.003) and the PPCS controls (p = 0.001) compared to 
healthy controls. Participants responded variably to the intervention, therefore case analyses 
were considered and revealed that some individuals responded to the intervention while 
others did not. Future studies with larger populations and longer follow-up times may help 
evaluate whether there are commonalities between positive responders. 
Keywords 
Concussion, persistent post-concussive symptoms, neurofeedback, LoRETA neurofeedback, 
heart rate variability biofeedback, biofeedback  
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1 Introduction 
1.1 Concussion and Persistent Post-Concussion Symptoms 
A concussion (often used interchangeably with mild traumatic brain injury) is defined as 
a traumatic brain injury that is induced by biomechanical forces, which results in an array 
of signs and symptoms that can include somatic, cognitive, behavioral, or emotional 
changes, sleep disturbances and or balance problems. Most concussions resolve 
spontaneously, but some studies indicate that as many as 43% of individuals continue to 
experience persistent and disabling problems months beyond their injury (1). Persistent 
post-concussive symptoms (PPCS) refer to the lack of clinical recovery in 10-14 days for 
adults, and four weeks for children (2). Persisting symptoms can lead to a condition 
known as post-concussion syndrome (PCS; 2).  
PPCS are problematic because they decrease quality of life by several means, such as 
reduced social interactions, difficulty continuing previously enjoyed past-times or 
resuming pre-injury physical capabilities and employment tasks (3). This is likely a factor 
that contributes to approximately 42% of individuals not returning to work in six months 
following a concussion (4). Further, 28% of those who do return to work following a 
concussion do not return to the same level of work as before their injury (4); many 
individuals require modified return to work duties. Returning to work while continuing to 
suffer PPCS increases the risk of subsequent concussions (Mansfield et al. 2015) and 
unintentional injury, such as falls and motor vehicle accidents (5).  
Recent literature has identified that PPCS are associated with various physiological 
impairments, including reduced cerebral vasoreactivity as the severity of PPCS increases 
(6), and reduced functional connectivity compared to healthy individuals (7). Increases in 
PPCS also correlate with reductions in white matter integrity, indicating delayed 
processing speed (8). These physiological deficiencies can manifest in numerous ways, 
such as reduced attention and focus, increased reaction time, and disruptions in vision; all 
factors necessary for the safe operation of a motor vehicle (9) 
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1.2 Concussion, PPCS and Driving 
Driving requires planning, anticipation, foresight, concentration, inhibition of certain 
stimuli, problem-solving, the ability to simultaneously process large amounts of stimuli, 
and quick reactions, all of which can be impaired by a brain injury (10). It has been 
suggested that individuals who experience a concussion should not drive for 24 hours 
(11). But, driving restrictions for individuals with PPCS depends on medical 
professional’s discretion, which is influenced by type and severity of symptoms (11). 
Usually driving capacity is initially evaluated by a medical professional, but only 49% of 
physicians ‘almost always’ provide driving guidance following a concussion (12). A lack 
of driving guidance is concerning because failing to do so may result in returning to 
driving prematurely. This is illustrated through findings such as 66% of collegiate 
athletes continue to drive following a concussion (13). Furthermore, I am not aware of 
any research-based recommendations regarding driving with PPCS.  
In a subjective questionnaire, more than half of the participants continuing to experience 
PPCS 15 months (on average) post-injury indicated that they were experiencing 
difficulties with fatigue, concentration, memory, anger and anxiety that impacted their 
overall daily activities (14). This study identified that these participants developed coping 
mechanisms to compensate for their difficulties while driving, including avoiding rush 
hour traffic, breaking up drives and minimizing lane changes. Although these adaptations 
may allow these participants to drive, not everyone experiencing PPCS is able to make 
these adaptations. For that reason, identifying and trying to fix the source of the problem 
would be much more beneficial.  
Making matters even more complex, resolution of concussive symptoms does not 
necessarily indicate a return to pre-concussion functioning. Individuals who suffered a 
concussion but are asymptomatic exhibit reduced driving capabilities, as assessed in a 
driving simulator (15). Their deficiencies included more frequently crossing over the 
road’s edge and weaving within their lane when navigating curves. Recently concussed 
individuals (two weeks to three months post-concussion) also exhibit increased reaction 
time during simulated driving performance (16), and delayed traffic hazard perception 
(17). Additionally, compared to the general population, accident rates are more than 
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double for persons six to nine years following traumatic brain injury (18). The 
combination of physiological deficits in those experiencing PPCS, as well as reduced 
driving performance in people after a concussion or traumatic brain injury, emphasize the 
need to evaluate driving performance in individuals with PPCS. 
1.2.1 Simulated Driving 
Driving simulators are a valuable alternative to on-road driving assessments because they 
provide a safe environment and allow scripted events to happen for each participant (19). 
They have successfully been used to evaluate the driving habits of various populations, 
including older adults (20), individuals with glaucoma (21), and people with multiple 
sclerosis (22). Driving simulation has also proven effective for providing driving 
education to adolescent drivers (23, 24). Driving simulation can offer a valid and reliable 
assessment of driving performance (19), and reflects real-life driving (25). Furthermore, 
simulator-based assessments can also be more sensitive than an external rater to long-
term driving performance in individuals with a traumatic brain injury (26). 
Limited previous literature has evaluated the effects of concussion and PPCS on driving, 
therefore it is difficult to know what variables should be evaluated. Some of the observed 
variables have included reaction time from the moment a programmed stimulus appeared 
to the time of an evasive maneuver (e.g. pressing the brake or evasive steering; 16), as 
well as number of traffic law violations, crashes, lane excursions, lane position and speed 
(15).  
1.3 Concussion, PPCS and Mental Health 
Concussions are often associated with anxiety, depression, mood changes, and poor 
global health (27). These difficulties can continue for individuals with PPCS, but it is 
unclear whether PPCS is the cause or merely an association. Some evidence suggests that 
psychological factors such as legal involvement and premorbid psychological illnesses 
contribute to the development and continuation of PPCS (28). Additionally, a lower level 
of psychological resilience, increased trait anxiety and embitterment can affect the 
emergence and continuation of PPCS (29).  
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PPCS also impacts aspects of life satisfaction. For example, individuals with PPCS report 
a low self-assessed quality of life (30). Reported difficulty initiating and staying asleep 
(31), as well as migraine and tension-type headaches (12), also contribute to life 
dissatisfaction. Following a concussion, depression is associated with greater 
psychosocial dysfunction, more psychological distress, and more neurobehavioral 
dysfunction (27). This results in a negative cycle, where difficulty continuing normal 
activities results in a reduction of those activities, which increases psychosocial 
dysfunction and psychological distress, and the cycle continues. 
Mood disruptions resulting from (or in combination with) PPCS can influence 
fundamental components of driving. Individuals with major depressive disorders perform 
worse on working memory tasks (32), have slowed reaction time, and are susceptible to 
fatigue (33). Additionally, increased anxiety can draw focus to threat-related stimuli, 
which reduces concentration and information processing (34). Increases in impulsivity, 
irritability and aggression (35) can also result in dangerous and at-risk driving 
behaviours.  
1.4 Generalized Anxiety Disorder Scale  
Anxiety is one of the most common PPCS (35). The 7-item Generalized Anxiety Scale 
(GAD-7) detects generalized anxiety, and can also detect post-traumatic stress disorder, 
panic disorder and social anxiety disorder (36). It is a reliable and valid measure of 
anxiety in the general population (37), the elderly (38) and in primary care (39). It is 
preferred for individuals with PPCS because they often experience vision difficulties and 
headaches with prolonged reading and concentration, and this questionnaire is very short. 
1.5 Rivermead Post-Concussion Symptoms Questionnaire 
Questionnaires have been created to evaluate some of the most common concussion 
symptoms. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) is a 16-item 
questionnaire that evaluates the severity of symptoms such as headache, dizziness, 
nausea, poor concentration, forgetfulness, etc. It demonstrates good test-retest and inter-
rater reliability (40). Furthermore, when evaluating headaches, dizziness and nausea 
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separately from the remaining 13 items, it has a good test-retest reliability and validity at 
three months post injury (41). It is also very short, and therefore is easy for individuals 
with PPCS to complete.  
1.6 Treatment of Concussion and PPCS 
Since the return protocol for acute concussions is well-established (2), it can easily be 
adhered to and implemented by medical professionals. When an individual suffers a 
concussion, they often are instructed to follow a graded return to work/learn/play 
protocol. They begin with a 24-48 hour cognitive and physical rest period. Afterwards, 
they continue gradually returning to everyday activities, while reducing this activity if 
symptoms increase (2). This protocol facilitates proper immediate treatment, and may 
help increase the likelihood of resolution.  
PPCS, however, is much more difficult to treat because the best practices for 
rehabilitation programs have not yet been universally adopted. Individualized treatment 
plans that target medical, physical and psychosocial symptoms are recommended (2). 
Accordingly, specialists like physiotherapists, occupational therapists, speech and 
language specialists, optometrists, or massage therapists may be consulted. Patients may 
also seek psychological treatment to aide common symptoms like depression, anxiety, or 
mood changes (42).  
Although these specialists may reduce or eliminate symptoms, this is not always the case. 
For instance, treating the manifested symptoms does not necessarily address the cause; 
the root of the symptom may be due to altered physiology. This is starting to be 
researched more. For example, exercise used to be discouraged for individuals 
experiencing symptoms following a concussion (43). But, we now know how beneficial 
sub-symptom aerobic exercise following a concussion can be (44). Treating the 
manifested symptom may be beneficial and allow individuals with PPCS to live with 
their injury, but research needs to be done to investigate how to identify the physiological 
damage and how to rectify it.  
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1.7 Heart Rate Variability 
Biomechanical forces that result in concussions affect other organs within the body, not 
just the brain (Cernak and Noble-Haeusslein, 2009). Furthermore, if an organ and the 
organ’s control center (the brain) are injured, it can result in additional difficulties. For 
example, the autonomic nervous assists in controlling the heart, including whether the 
heart should increase or decrease its strength and rate of heart beats (45). The specific 
regions of the brain that are involved in regulation of the autonomic nervous system are 
still debated, but it has been determined that it includes contribution from areas such as 
the amygdala and prefrontal cortex (46). This information indicates that there is a brain-
heart connection, and a disruption to this connection (e.g. following a concussion) can 
result in a cascade of symptoms that can include arrhythmias, ischemia, myocardial 
infarction, and altered sympathetic or parasympathetic activation (Leddy et al., 2007).  
Heart rate variability (HRV) is the natural beat-to-beat variability in heart rate. It is 
representative of autonomic function and sympathetic-parasympathetic balance (47). It 
can be measured in both time- and frequency-domains, including measures such as the 
square root of the mean squared differences of consecutive normal intervals (RMSSD), 
and standard deviation of the normal interval (SDNN). SDNN is a good global measure 
of variability and it reflects cardiovascular adaptability to individual and environmental 
changes (48). Frequency-domain measures include power in various bands (49).  
Healthy people normally exhibit a beat-to-beat variation in their heart rate, but HRV is 
decreased when the autonomic nervous system is impaired (50). Decreased HRV is 
associated with reduced social and emotional functioning, including social cognition, 
empathy and alexithymia (48). HRV is altered in those suffering a concussion, including 
low amplitude and reduced rhythmicity (Thompson and Hagedorn, 2012). Further, some 
individuals suffering PPCS have reduced parasympathetic activity and hyperactive 
sympathetic activity and heart rates (51). This is problematic because it results in a 
heightened and prolonged state of flight or flight, which may contribute to feelings of 
nausea, dizziness, and inability to sleep – all of which are common PPCS (2).  
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HRV biofeedback intends to repair sympathetic-parasympathetic balance, as well as 
baroreflex activity (Lehrer et al., 2003). Using an electrocardiograph (ECG), it provides 
beat-to-beat data to a participant while they maintain a slow, set breathing rate. This set 
breathing rate maximizes respiratory sinus arrhythmia, which increases the heart rate 
when inhaling, and decreases the heart rate when exhaling (52). Respiratory sinus 
arrhythmia works in combination with the information that baroreceptors are detecting 
regarding blood pressure to increase the variability of HRV (53). More variability 
(increased HRV) reflects increased reflex efficiency, which is a result of more controlled 
autonomic activity (54). It also translates to larger oscillations in heart rate, which 
promotes increased parasympathetic control and reduced sympathetic control (55).  
A recent review on HRV biofeedback research shows that it may positively affect 
illnesses such as asthma, COPD, irritable bowel syndrome, cyclic vomiting, recurrent 
abdominal pain, fibromyalgia, cardiac rehabilitation, hypertension, chronic muscle pain, 
pregnancy induced hypertension, depression, anxiety, post-traumatic stress disorder, and 
insomnia (56). HRV biofeedback improves cognitive functioning and emotional 
regulation in some individuals experiencing a brain injury (48). It may also contribute to 
improved attention (57), enhanced executive functioning (58) and superior problem-
solving abilities (59). Research is limited on HRV biofeedback’s effects on PPCS, but it 
has been indicated that it may be effective with this patient group in reducing symptoms 
(including headache) and increasing mood (60, 61). 
1.8 Neurofeedback 
Electroencephalograph (EEG) biofeedback (neurofeedback), has been used for decades to 
improve rehabilitation and brain function. It has been used to improve attention, impulse 
control (62), agreeableness and feelings of confidence and composure (63), and reduce 
stress (64). It also helps reduce the symptoms of illnesses such as attention deficit 
hyperactive disorder (65), post-traumatic stress disorder (66), depression (67), and 
epilepsy (68). Neurofeedback has evolved from measuring brain surface area activity, to 
source localization of neural activity. This form of neurofeedback is known as low-
resolution electromagnetic tomography (LoRETA) neurofeedback (69). It uses 
information from the electrical leads placed on the scalp to derive a 3D representation of 
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the activation of various regions of the brain– not just where it has manifested on the 
superficial area of the brain/scalp. LoRETA neurofeedback allows the user to see, in real 
time, the amplitude of electrical activity at specific brain regions, and they can therefore 
self-regulate this electrical activity (69). 
Benefits to LoRETA neurofeedback include that it is a non-invasive procedure, and that it 
shows functional activity in specific brain regions. LoRETA neurofeedback also enables 
individualized rehabilitation, which is one of the biggest limitations of traditional brain 
injury interventions (70). Based on operant-conditioning principles, users receive 
feedback on their brain activity, which is expressed as z-scores relative to a normative 
population (healthy age-matched population). This activation is associated with some 
form of audible or visual cue (e.g. music playing or a light turning on), when brain 
activity is within the set range compared to the healthy population (i.e. correct). Over 
time, users learn to exhibit correct brain activity. With more LoRETA neurofeedback 
experience, this trained activity can become more habitual, therefore leading to routine 
improvements (71). 
LoRETA neurofeedback commonly uses Brodmann areas to classify areas of deviant 
brain activity (72-74). Each area is associated with different cognitive functions; 
inappropriate brain activity (hyperactive or hypoactive) in different areas can be 
associated with specific PPCS (71). Since every PPCS case is unique, it requires an 
individualized LoRETA neurofeedback treatment protocol. This makes it difficult to 
perform standardized studies, because a blanket treatment will not necessarily work when 
each person demonstrates inappropriate brain activity in different areas of the brain.  
The majority of research regarding LoRETA neurofeedback treatment for various 
ailments is based on case studies. For example, LoRETA neurofeedback improved 
memory, attention, and global cognitive scores in eight participants with cognitive 
dysfunction and dementia (75).  Additionally, LoRETA neurofeedback has provided 
cognitive enhancement in individuals with a traumatic brain injury (72). LoRETA 
neurofeedback has also proven beneficial for PPCS in small case studies (76). 
Accordingly, LoRETA neurofeedback seems to be effective for several clinical 
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conditions, but systematic studies with larger sample sizes needs to be completed in order 
to evaluate the effectiveness of LoRETA neurofeedback for individuals with PPCS.  
LoRETA neurofeedback is often used as a treatment modality in conjunction with HRV. 
This is because the neuroanatomical networks and structures that affect and control HRV 
can be influenced by neurofeedback; therefore, changes in HRV can cause changes in 
these neuroanatomical networks and structures (77). Combining these modalities can be 
effective when treating individuals with anxiety and depression (78), as well as 
individuals with traumatic brain injury (79).  
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2 Purpose and Hypothesis 
2.1 Purpose 
The purpose of this thesis was to determine whether HRV biofeedback in combination 
with LoRETA neurofeedback could reduce symptoms and/or improve simulated driving 
performance in individuals suffering from PPCS. 
2.2 Hypothesis 
1. Individuals with PPCS that receive HRV biofeedback and LoRETA neurofeedback 
will have reduced symptoms after an eight-week intervention, compared to a group with 
PPCS that does not receive HRV biofeedback and LoRETA neurofeedback.  
2. Brain activity in specific areas will be normalized in individuals with PPCS who 
receive LoRETA neurofeedback and HRV biofeedback, compared to people with PPCS 
who do not receive the intervention, and also to a healthy control group.  
3. Individuals undergoing an intervention involving HRV biofeedback and LoRETA 
neurofeedback will exhibit greater performance improvements in the driving simulation 
task compared to individuals with PPCS who do not receive the intervention, and 
compared to a healthy control group.   
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3 Methods 
3.1 Participants 
Thirty-one individuals were recruited to participate in this study; which was approved by 
Western University Health Science Research Ethics Board (Appendix A). Participants 
with PPCS had to be 18 years of age or older, have previously suffered a clinically 
diagnosed concussion, completed the BrainEx 90 concussion rehabilitation program, and 
still experiencing ongoing symptoms. They also had to be fluent in English, hold a valid 
driver’s license, and be capable of using hand-held devices. Healthy participants also had 
to be 18 years of age or older, have not suffered a concussion in the last two years, be 
fluent in English, and hold a valid driver’s license.  
Participants were withdrawn from the study if they were unable to complete the entire 
baseline assessment. This resulted in the loss of seven participants that experienced a 
worsening of symptoms and could not complete the driving simulator task. Therefore, 16 
participants with PPCS were randomized into the intervention and control groups, and 
eight healthy individuals were part of the healthy control group. This resulted in seven 
participants in the intervention group (48.6  13 years old, four females), nine 
participants in the PPCS control group (54.6  7.6 years old, six females), and eight 
healthy control participants (50.1  15.5 years old, four females). 
Information about the participants’ PPCS were collected during the baseline assessment. 
All PPCS individuals (intervention and control participants) reported that they continued 
to experience headaches, along with a variety of other symptoms. Six (of seven) 
intervention participants reported experiencing emotional changes (anxiety, anger, 
inability to regulate emotions), and four (of seven) reported experiencing balance 
problems. Additionally, three (of seven) intervention participants reported experiencing 
dizziness, light sensitivity, memory problems, difficulty focusing, and feelings of 
overstimulation. Eight (of nine) PPCS controls reported experiencing noise sensitivity, 
six reported experiencing light sensitivity, and five reported experiencing emotional 
changes (anxiety, anger, inability to regulate emotions) and balance problems. 
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3.2 Intervention Protocol 
3.2.1 Baseline and Follow-Up Assessment 
Participants were initially contacted via email about interest in the study; their response 
prompted an informational email. They then met with a study investigator at the iMobile 
Research Lab at Western University, where together they reviewed the letter of 
information. Once all questions were answered and they signed the consent form, the 
baseline assessment began. 
The participant was first measured and fitted with a 19-lead EEG cap (Electro Cap 
International, Eaton, Ohio). Each electrode placement corresponded to specific locations 
on the scalp according to the 10-20 International System for electrode placement (80). 
The leads were then filled with a water-soluble conducting gel (Electro-Gel, Electro Cap 
International, Eaton, Ohio). An abrasive gel (NuPrep) was used as skin preparation for 
the attachment of an electrode to each earlobe. Additionally, one electrode was also taped 
to the participants chest, below the left clavicle, for ECG monitoring.  
The participant then completed three individual brain function assessments. First, they sat 
still and silent for five-minutes for eyes open EEG recordings. As sensitivity to light and 
screens can be problematic for individuals suffering PPCS, they were instructed to look at 
a spot on the wall. Afterwards, they had a three-minute resting EEG measurement taken 
with their eyes-closed. Finally, they performed a 10-minute reaction time test, where they 
pressed a button on a handheld toggle when a large blue circle appeared. Before they 
completed the actual reaction time test, they had to pass a pre-test that had the same rules, 
but provided immediate feedback about whether the responses were correct/incorrect in 
pressing/not pressing the button. All of this was completed with the study investigator in 
the neighboring room so as to not distract or stress the participant. There was a one-way 
window for the study investigator to observe the participant, and the participant was 
informed that they could either wave or call on the investigator if they had any questions 
or issues. 
Brain function assessment was followed by a break. Afterwards, the participant 
completed the RPQ and GAD questionnaires (Appendices B and C), and then proceeded 
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to the driving simulation task. This was performed on a CDS-200 DriveSafety 
simulator, which includes a steering wheel and dash display from a Ford Focus, a gas and 
brake pedal, and three computer screens for viewing. The simulator was adjusted for the 
participants comfort, ensuring that they were the appropriate distance from the screens, 
and they were comfortable with the height and tilt of the steering wheel and distance to 
the pedals. 
The simulation drive began with three acclimation drives, which are part of an evidence-
based simulator sickness mitigation protocol in the iMobile laboratory (24). The 
acclimation drives included driving straight down the road at 50 km/hour with no other 
vehicles on the road, driving around a city block involving four consecutive left-hand 
turns while navigating traffic, and lastly driving around a city block involving four 
consecutive right-hand turns while navigating traffic. Between each acclimation drive, 
participants were screened for symptoms of simulator sickness using a modified version 
of the motion sickness assessment questionnaire (81). Participants rated feelings of 
sweatiness, dizziness, and potential to vomit on a scale of 1 (not at all) to 10 (severely). 
Participants also had the option to take breaks between drives as needed.  
Finally, participants performed one of two simulator drives. Participants were informed 
that the drive was supposed to simulate driving in the real world, so they were informed 
that other drivers may not obey traffic laws as expected. The two simulator drives 
contained identical elements, but in different orders. Both drives ended at a highway on-
ramp, and they were instructed to either go towards London or Toronto, depending on 
which simulation drive they were completing. The drive was approximately 10 minutes 
in length, and included five scripted events: an unexpected pedestrian crossing the street 
in front of the car; a car making a rapid lane change in front of the driver; a sudden 
change in traffic lights from green to yellow (go-no-go); a way-finding task 
(appropriately picking the ramp to London or Toronto based on earlier instruction); and a 
car suddenly pulling out of a driveway in front of the participant. As we are interested in 
measures of driving performance that are directly related to safety, we evaluated the 
participant’s responses related to two of the scripted events that involve responding to 
critical roadway information: the unexpected pedestrian crossing the street in front of the 
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car and a car suddenly pulling out of a driveway in front of the car. In specific, we 
quantified the participants’ reaction times between the onset of the scripted event (e.g. 
first appearance of the pedestrian) until the participant responded by steering or braking. 
We also evaluated whether the participants were in a collision during their driving 
simulator task. Involvement in a collision ended the driving simulation, which may have 
prevented the participant from completing the pedestrian crossing or car pull-out scripted 
event. The mean lane deviation for the duration of the driving simulation task was also 
evaluated, using the average deviation from the center of the lane.  
After eight weeks, all participants returned to complete another brain function 
assessment, RPQ and GAD, and driving simulator acclimation and drive. The final 
simulator drive was the alternate drive they had not completed in their baseline 
assessment. For example, if they completed Drive 1 in their baseline test, then they would 
complete Drive 2 in their follow-up assessment.  
 
3.2.2 LoRETA Neurofeedback and HRV Biofeedback 
Intervention 
Participants in the intervention group received an Android tablet (either a Craig 7" 1GB 
6.0 “Marshmallow” Tablet, New York, New York or a Samsung Galaxy Tab A 7’ 8GB 
Android 5.1 “Lillipop” Tablet, Seoul, South Korea) and heart rate variability training tool 
(Evoke Waveband, Evoke Neurosciences, New York, New York) upon completion of 
their initial assessment. They were shown how to use the equipment, and instructed that 
they should perform a HRV biofeedback session every morning and night for eight 
weeks. Each HRV biofeedback session involved placing the Waveband just below their 
elbow, opening the application on their tablet (Mindja, Evoke Neurosciences, New York, 
New York), and doing a 5-minute exercise in which they were cued to breathe at their 
resonant frequency (approximately six breaths per minute; 82). Points were awarded as 
their HRV improved. Participants were also provided with a log book to record the dates 
and times of their completed sessions. 
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LoRETA neurofeedback is based on measuring EEG signals, comparing them to age-
matched population norms, and providing feedback to normalize deviant signals. We 
performed these measurements using a 19-lead EEG cap (Evoke Neurosciences, New 
York, New York). Assessments were completed at the iMobile research laboratory at 
Western University, London, Ontario, and interventions were completed in a private 
room at Parkwood Institute, London, Ontario. Each participant in the intervention group 
was scheduled to participate in three sessions per week (usually Mondays, Wednesdays, 
and Fridays), for 8 consecutive weeks. This totaled an expected 24 LoRETA 
neurofeedback sessions and 112 HRV biofeedback sessions (24 of which to be completed 
with the study investigator during the regularly scheduled neurofeedback training 
sessions). Typically, their sessions were at the same time of day.  
Based on their initial assessment, an individualized LoRETA protocol was developed for 
each participant. This involved identifying the Brodmann areas of the brain and the EEG 
frequencies that were most deviant from age-based normal values, and targeting them for 
biofeedback. The set of Brodmann areas and frequencies were constant for each of the 
participants throughout the study. Each LoRETA neurofeedback session was broken up 
into 10 exposures of two-minute duration, for a total of 20 minutes of training. 
Participants were instructed to “relax, focus, and turn on the green light”, which would 
appear on a computer screen in front of them. The light turned green when the 
participants were appropriately activating the target cerebral areas at the appropriate 
amplitude. Throughout the duration of the study, as participants achieved more success 
(having the green light on >80% of the time), the stringency of their target (the magnitude 
of the deviation) was reduced, making it more difficult. The goal was to have the green 
light on for 70-80% of the time, creating a balance of reward and challenge.  
Following the 20-minute LoRETA neurofeedback training, participants completed a five-
minute HRV biofeedback session. The same HRV biofeedback exercise was completed 
as described above (which included a five-minute guided breathing exercise at a rate of 
approximately six breaths per minute). This HRV biofeedback session counted as one of 
their two daily HRV biofeedback sessions, and was recorded in their log books.  
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3.2.3 EEG Collection and LoRETA Neurofeedback 
EEG was collected using the eVox System (Evoke Neuroscience, New York, New York), 
which is a portable hardware and software system for measuring electrophysiological 
data and performing various biofeedback sessions (surface neurofeedback, LoRETA 
neurofeedback, and HRV biofeedback). The eVox system consisted of a laptop, an 
amplifier, a response button, and a 19-lead EEG cap. When using the system, the cap was 
placed on the participant so that the 19 electrodes were situated on the head according to 
the 10-20 International System for electrode placement (80). The cap was then connected 
to the amplifier, which measured the EEG and ECG data and wirelessly transmitted them 
to the laptop. This setup was utilized for the LoRETA neurofeedback and also the EEG 
data collection.  
 
3.2.4 Driving Simulator Collection 
Performance on the CDS-200 DriveSafety simulator was collected and stored from the 
entire drive, with metrics collected at 50 Hz. This included vehicle speed, heading, and 
position within the lane. In addition, information was collected during each scripted event 
(e.g. the unexpected pedestrian crossing onto the roadway). Data collected also included 
metrics such as the distance to objects in the scripted events, and activation of the 
steering wheel, brake and gas pedal.  
 
3.3 Data Analysis 
3.3.1 RPQ and GAD 
Total scores on the GAD for each participant were summed and change from baseline to 
follow-up was calculated. Comparisons of this change were analyzed between the 
intervention, PPCS control, and healthy control groups using a one-way analysis of 
variance (ANOVA). RPQ outcomes were tallied as two scores, similarly to previous 
research (41). The headache, nausea and dizziness scores were tallied, and the remaining 
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questions were tallied separately. The statistical significance of differences from baseline 
to follow-up between the three participant groups in both RPQ sub scores were assessed 
using one-way ANOVAs.  
 
3.3.2 Driving Simulation Task 
Three parameters were assessed during the driving simulation, including the reaction time 
for two of the specific scripted events (the unexpected pedestrian crossing and the car 
pulling out in front of the driver’s simulated vehicle). Reaction times were assessed by 
evaluating the time difference between the start of the hazardous event and when the 
participant applied pressure to the brake or suddenly changed their lane deviation (i.e. 
swerving). Additionally, average lane deviation was calculated using the magnitude of 
deviation from the center of the lane at 50 Hz throughout the drive. This was measured in 
meters, and averaged over the span of the participant’s drive. The statistical significance 
of differences from baseline to follow-up between the three participant groups were 
analyzed using a one-way ANOVA. 
 
3.3.3 HRV and EEG 
HRV was represented by the SDNN parameter (48). SDNN was expressed as a change 
from baseline to follow-up, and analyzed using a one-way ANOVA. 
Participants’ EEG results included the z-scores of the EEG amplitude for frequencies  
between 2 and 30 Hz at all 47 Brodmann areas (83). This yielded a rich data set with a 
total of 1288 EEG parameters per participant. Brodmann areas with the most deviation 
(12 areas maximum) were identified for all participants in the initial assessment, and 
were the chosen intervention target areas. Mean changes from baseline to follow-up 
within the designated target Brodmann areas, at all frequencies (2-30 Hz), were 
calculated. The statistical significance of differences from baseline to follow-up between 
the three participant groups were analyzed using a one-way ANOVA. 
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3.3.4 Statistical Analysis 
All statistical analyses were performing using commercial software (SPSS 25, IBM 
Corp., Armonk, NY). All one-way ANOVA analyses followed the same protocol. 
Outliers were assessed using boxplots, and identified outliers were considered on a case-
by-case basis. Normality of the distribution was assessed using a Shapiro-Wilks test. 
Levene’s statistic was used to evaluate homogeneity of variances, and if the threshold for 
homogeneity of variances was not met, a Welch ANOVA and Games-Howell post hoc 
was used. If the homogeneity of variances assumption was met, a Tukey post hoc was 
used. The threshold for significance was set at p = 0.05 for all tests. Normality of 
distribution and homogeneity of variances are assumed unless otherwise stated.    
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4 Results 
4.1 Compliance 
Participants in the intervention group attended 88% of their LoRETA neurofeedback 
sessions (21  2.56; the 25th, 50th, and 75th percentiles were 18.5, 22 and 23, 
respectively). The range extended from a low of 17 (one participant) to a maximum of 24 
(two participants). Additionally, participants on average completed 86% of their HRV 
sessions (96.71  10.14; the 25th, 50th, and 75th percentiles were 86, 99, and 106, 
respectively). The range extended from a low of 83 (two participants) to a maximum of 
111 (one participant).   
4.2 GAD and RPQ 
Each group’s average change in GAD scores decreased from baseline to follow-up 
(Figure 1). There were no differences (F = 0.528, p = 0.597) between groups, but there 
was a large amount of variability in the change data. This variability reflects that some of 
the participants in each of the groups showed no change or improvements while others 
showed decrements (Figure 2). Additionally, the remaining RPQ measures parameter 
identified no significant differences between groups (F = 0.090, p = 0.914; Figure 3).  
The one-way ANOVA revealed that there were statistically significant differences in 
headache, nausea, and dizziness between the three groups (F = 10.088, p = 0.001). Post-
hoc testing showed that the healthy control group had significantly greater decreases than 
the intervention group (p = 0.003) and the PPCS control group (p = 0.001). The 
difference between the intervention group and the PPCS control group was not significant 
(p = 0.935; Figure 5). There was also a large amount of variability in both RPQ parameter 
measures, therefore individual measures for remaining RPQ measures, along with 
headache, nausea, and dizziness, are provided (Figure 4 and Figure 6, respectively).   
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Figure 1. Average change in GAD scores between groups. Boxes reflect the 
interquartile range, whiskers reflect the minimum and maximum values, and dots 
represent outliers. 
 
Figure 2. GAD Scores for the individual participants. Green indicates participants in 
the intervention group, grey indicates PPCS controls, and black indicates healthy 
controls. 
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Figure 3. Average change in remaining RPQ scores between groups. Boxes reflect 
the interquartile range, whiskers reflect the minimum and maximum values, and dots 
represent outliers. 
 
Figure 4. RPQ Scores for the individual participants on the remaining items. Green 
indicates participants in the intervention group, grey indicates PPCS controls, and black 
indicates healthy controls. 
Intervention PPCS Control Healthy Control
C
h
an
ge
 in
 R
P
Q
 S
co
re
s 
fo
r 
R
em
ai
n
in
g 
M
ea
su
re
s
-20
-15
-10
-5
0
5
10
15
0
5
10
15
20
25
30
35
40
45
50
Baseline Follow-Up
R
P
Q
 S
co
re
s 
fo
r 
R
em
ai
n
in
g 
M
e
as
u
re
s 
(O
u
t 
o
f 
5
2
)
22 
 
 
Figure 5. Average change in headache, nausea, and dizziness RPQ scores between 
groups. Boxes reflect the interquartile range, whiskers reflect the minimum and 
maximum values, and dots represent outliers. 
 
Figure 6. RPQ Scores for the individual participants on headache, nausea, and 
dizziness. Green indicates participants in the intervention group, grey indicates PPCS 
controls, and black indicates healthy controls. 
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4.3 Driving Simulation 
Ten participants were involved in a collision during their driving simulator task. Eight 
collisions occurred in the initial assessment (two from the intervention group, four from 
the PPCS control group, and two from the healthy control group) and two occurred in 
their follow-up assessment (both from the PPCS control group). Accordingly, full drive 
metrics were not available for some participants. This resulted in the analysis of changes 
in reaction time to a vehicle pulling out in front of the participant in five intervention 
participants, five PPCS participants, and four healthy controls. Analysis revealed a lack 
of homogeneity of variances (p = 0.024), so a Welch ANOVA was performed. This 
analysis identified that there were no significant group differences (F = 2.223, p = 0.167) 
between the intervention group (-0.93 s  1.03, 95% CI = -1.89, 0.03), the PPCS control 
group (-0.01 s  0.43, 95% CI = -0.40, 0.39) and the healthy control group (-0.37 s  
0.59, 95% CI = -0.87, 0.48). 
The participants that were involved in collisions also effectively reduced the number of 
participants that were exposed to the pedestrian walking out scripted event. The reaction 
time in response to the pedestrian walking out in front of the vehicle was analyzed in six 
intervention participants, eight PPCS control participants, and seven healthy controls. 
The intervention group had an average reduced reaction time of -0.51 s  0.74 (95% CI = 
-1.29, 0.27), the PPCS control group had an average reduced reaction time of -0.31 s  
0.70 (95% CI = -0.90, 0.27) and the healthy control group had an average reduced 
reaction time of -0.20 s  0.42 (95% CI = -0.99, 0.25). There were no statistically 
significant differences between groups (F = 0.144, p = 0.867). Lastly, there was a trend 
towards significant differences in mean lane deviation change between groups (F = 
3.102, p = 0.067). The intervention group increased by -0.03 m  0.08 (95% CI = -0.04, 
0.11), the PPCS control group increased by 0.10 m  0.10 (95% CI = 0.03, 0.19) and the 
healthy control group decreased by -0.01 m  0.11 (95% CI= -0.11, 0.09). 
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4.4 HRV 
Initial and follow-up SDNN measures were compared between groups, with no 
significant differences between groups identified (F = 0.267, p = 0.768). The intervention 
group had an average SDNN decrease of -0.86 ms  16.27 (95% CI = -15.90, 14.18), 
while the PPCS control group had an average decrease of -7.79 ms  17.10 (95% CI = -
20.92, 5.37) and the healthy control group had an average decrease of -4.71 ms  22.83 
(95% CI = -25.83, 16.40). 
 
4.5 EEG 
One extreme outlier was identified in the healthy control group, therefore their EEG 
assessments were excluded from analysis. This approach was similar to other researchers 
(84). Differences in EEG did not have homogeneity of variances (p = 0.04). The Welch 
ANOVA identified a significant difference between groups (F = 23.262, p < 0.005). The 
intervention group had significantly greater normalization of their EEG in the target areas 
(smaller z-score deviations) than the PPCS control group (p < 0.0005). There were no 
significant differences between the PPCS control group or the intervention group and the 
healthy control group (p = 0.448 and 0.113, respectively; Figure 7). 
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Figure 7. Average change in the normalized EEG z-score deviations between 
groups. Boxes reflect the interquartile range, whiskers reflect the minimum and 
maximum values, and dots represent outliers.  
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5 Discussion 
Our intervention implemented a combination of LoRETA neurofeedback and HRV 
biofeedback in individuals with PPCS, and compared a multitude of outcome measures to 
participants with PPCS that did not receive the intervention, and a healthy control group. 
Individuals that received the intervention exhibited reduced EEG z-score deviations 
compared to the PPCS control group. Individuals in the intervention group also reported 
frequency and/or severity reductions in headache, nausea, and dizziness compared to the 
healthy control group. However, there were also differences between the PPCS control 
group and the healthy control group. For example, the PPCS control group’s remainder 
RPQ scores showed less of a change in comparison to the healthy control group, likely 
reflecting functional impairments in participants with PPCS compared to healthy 
controls. There were also no statistically significant differences in GAD scores, driving 
simulation performance, or HRV between the three groups. Therefore, our findings 
support our hypothesis that LoRETA neurofeedback and HRV biofeedback contribute to 
reducing EEG z-score deviations.  
Some research has identified that EEG z-scores can represent difficulties balancing 
concentration and relaxation (85). This lack of flexibility is problematic because it can 
result in wasted energy, or an inability to generate energy for an upcoming task. LoRETA 
neurofeedback evaluates the function of specific brain areas, enabling determination of 
the link between symptoms and brain function. For example, Brodmann area 10 is 
responsible for concentrating on one’s own thoughts or paying attention to the external 
environment (86). This was a common neurofeedback target area for the participants with 
PPCS in this thesis, which may reflect the concentration difficulties that are typical in 
individuals with a concussion (14). Therefore, a reduction in EEG z-score deviations may 
have important practical implications. For example, the subset of study participants that 
showed reductions in z-score deviations also showed congruous changes in their 
concussion symptom scores.   
We observed reduced EEG z-score deviations in the intervention group compared to 
PPCS controls, but these EEG changes were not associated with reduced PPCS, as 
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hypothesized. However, we did observe a large amount of variation in the subjective 
assessment outcomes between individuals. When interpreted clinically, this is important 
because it represents a disparity in the effectiveness this intervention; some participants 
experienced a reduction in symptoms, while others experienced an increase. This was 
also noted in the PPCS control group, and further supports the individuality of each 
person with PPCS (2). Therefore, similarly to many other PPCS rehabilitation practices, 
this intervention does not appear to be effective for everyone with PPCS (87, 88). 
Research regarding commonalities between responders would help indicate patients who 
would most likely benefit from this treatment.  
Similarly to PPCS symptoms, reductions in EEG z-score deviations were not associated 
with improvements in driving performance, such as reaction time or lane deviation. But, 
the intervention group did exhibit a smaller magnitude increase in the average lane 
deviation compared to the PPCS control group. The magnitude of lane deviation in the 
intervention group was more similar to the healthy control group than the PPCS control 
group; this trend approached statistical significance. The intervention group also 
exhibited a trend towards decreased reaction time to respond during both of the scripted 
events: when the pedestrian walked in front of the car, and when the car pulled out in 
front of the participant, though these changes were not statistically significant. When 
applied to actual driving, decreases in reaction time may reduce the risk of a collision 
(89). Therefore, larger studies are encouraged in order to definitively evaluate the 
effectiveness of this intervention on driving reaction time. It should also be noted that the 
confidence intervals were large for each driving simulator parameter, which further 
indicates that there was a large amount of inter-individual variation in the effectiveness of 
this intervention.  
Despite HRV training, there were no significant differences in SDNN between groups, 
and the 95% CIs indicated that the changes in SDNN between baseline and follow-up 
assessments for all of the groups were also not significant. But this does not necessarily 
indicate that the intervention did not have any effect on SDNN. Previous research has 
shown increases in SDNN during an intervention, but a return to normal at the end of 
treatment and at follow-up (90). Accordingly, the participants in the intervention group 
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may have exhibited changes during the intervention that reverted at the end of the study. 
Additionally, the intervention group did exhibit a trend toward attenuated SDNN 
reduction compared to both groups of controls, with some individuals from the 
intervention group showing improvement. Once again, this metric reinforces the 
variability of this intervention’s effectiveness. 
The large variation in the effectiveness of this intervention between participants indicates 
that some individuals responded, and others did not. Accordingly, it is appropriate to 
evaluate the features of individual cases to further explore these divergent responses. This 
is especially true when each participant in both of the control groups exhibited a range of 
changes in the various outcome measures. Two specific cases from the intervention 
groups are presented below to illustrate the scope of the responses: one non-responder 
and one responder.  
Example Non-Responder: Participant 338. This individual attended all of their LoRETA 
neurofeedback sessions (24 of 24) and reported that they completed most of their HRV 
sessions at home (71%). Following the eight-week intervention, this participant exhibited 
a small increase in SDNN (51 ms to 54 ms), which was moving in the direction of the 
minimum goal of 65 ms. They also exhibited an increase in deviation in four of the six 
identified Brodmann areas following the intervention (Figure 8). However, their 
subjective scores on the GAD and RPQ either showed minimal improvement or 
worsening following the intervention. Their total for headache, dizziness, and nausea 
decreased slightly from seven to six (out of a possible 12), while their remaining RPQ 
scores increased substantially from 10 to 20 (out of a possible 52). Finally, their GAD 
score increased from two to four (out of a possible 21).  
Example Responder: Participant 331: In contrast, participant 331 mainly exhibited 
improvements in their outcome measures following the intervention. This participant 
attended 83% of their LoRETA neurofeedback sessions, and reported that they completed 
95% of their HRV sessions. Following the eight-week intervention, their SDNN reduced 
from 28 ms to 24 ms, which is moving away from the minimum goal of 65 ms. They 
exhibited significantly reduced deviations in two of the four identified Brodmann areas 
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(Figure 9).  But, their subjective scores all improved, with headache, nausea and 
dizziness decreasing from nine to five. Further, their remaining RPQ scores decreased 
from 26 to 8, and their GAD scores decreased from 12 to two. Anecdotally this 
participant reported that their symptoms decreased so much that they thought that it may 
be appropriate to reduce their anxiety medication.  
 
Figure 8. Individual Brodmann area (BA) baseline and follow-up deviation in 
Participant 338. 
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Figure 9. Individual Brodmann area (BA) baseline and follow-up deviation in 
Participant 331.  
Although there was a large variation in the effectiveness of this intervention between 
participants, the concussed participants (intervention and PPCS control groups) also 
reported a diverse range of symptoms at baseline. Despite random assignment of 
concussed individuals into the intervention and control groups, the participants in the 
PPCS control group exhibited a greater range in the RPQ scores for the headache, nausea, 
and dizziness parameter, and a smaller range for the RPQ remaining measures parameter.  
These apparent differences in baseline subjective symptom scores may have influenced 
the effectiveness of the intervention. Furthermore, it is likely that there may be a complex 
relationship between the outcome measures in this study. For example, the intervention 
may have impacted symptoms, but not driving outcomes. Similarly, the intervention may 
have affected driving outcomes, but not SDNN. Other studies have used structural 
equation modeling to evaluate similar types of relationships (91), but this was not 
possible in the current experiment due to the relatively small number of participants. 
This study is not without limitations. One limitation included the fact that we did not 
consider the influence of medications that our participants may have been taking. This 
study did not consider or evaluate the use of medication, or any changes that may have 
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participants’ outcome scores. An additional potential limitation was that the number of 
LoRETA neurofeedback sessions differed between participants, based on compliance. 
Although providing neurofeedback three times a week was recommended by a licensed 
neurofeedback practitioner (92), some participants communicated that they experienced 
extreme fatigue (which contributed to reduced compliance). This may indicate that our 
choice of three neurofeedback sessions per week is not optimal. Previous biofeedback 
studies have used different number and frequencies of the neurofeedback sessions; one 
study used two to three LoRETA neurofeedback sessions per week, for 20 sessions (93) 
while another study used daily neurofeedback sessions (94). It is not clear whether the 
protocol in this thesis was optimal, and there does not appear to be any consensus on the 
best practices for LoRETA neurofeedback. Also, given the individuality of concussions, 
it may be that a patient-specific process is required rather than one protocol. 
The neurofeedback in this thesis involved simultaneous training of up to 12 Brodmann 
areas. Other studies have used a similar criterion for defining which sites should be 
targeted for neurofeedback, but have trained a smaller number of concurrent sites (94). 
Some of the participants in the intervention group succeeded with the larger number of 
concurrent training sites, as illustrated with the responder case report, but some 
participants did not appear to successfully normalize their brain activities. It is not clear 
whether the relatively large number of sites used for the LoRETA neurofeedback in this 
thesis may have contributed to these divergent responses. As well, each participant used 
the same training sites throughout the entire intervention while other studies updated the 
neurofeedback training sites between sessions (94). While there are merits to maintaining 
consistent training sites, it may not be optimal for recovery. 
Participants were responsible for reporting their participation in the HRV sessions, which 
can result in reporting inaccuracies. However, the investigators had three face-to-face 
interactions per week with all of the participants in the intervention group, which 
presumably may have increased compliance and reporting of the home HRV sessions.  
Our parameterization of the RPQ scores is also a limitation. We divided the RPQ into two 
scores by tallying the headaches, dizziness and nausea scores separately from the 
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remaining 13 items. This approach is similar to previous research (41), but more recent 
research into the structure of the RPQ has identified that it may be better to quantify the 
RQP using a four factor model, clustered as vision, vertigo, mood/somatic and cognitive 
domains (95). It is unclear how our parameterization of the RQP scores may have 
influenced the findings. 
This thesis only evaluated a subset of possible variables from the simulated driving 
performances. We focused on the reaction time in two of the five scripted events, and on 
the average lane deviation parameter. Research supports that reaction time is associated 
with individual accident involvement (96), supporting that this parameter has linkages to 
safety; however, our parameters may not reflect general aspects of driving skill. 
Furthermore, the lane deviation parameter that we analyzed, which evaluated average 
deviation over the span of the driving task, may not reflect safety-relevant behavior. For 
example, a scenario with one slow lane deviation in each lateral direction may have the 
same average lane deviation as a different scenario with more frequent and abrupt lane 
deviations, although the implications for safety are different (97). Therefore, abruptness 
of lane deviations, as well as number of lane deviations, may be more representative of 
at-risk driving behaviours.  Furthermore, we did not evaluate driving behaviours such as 
visual scanning, that are also related to safety (24).  
This study only looked at the immediate effects of the LoRETA neurofeedback and HRV 
biofeedback intervention. This approach is consistent with other neurofeedback studies 
(62, 63, 98). However, it is not known whether changes will remain in the longer-term. 
Alternatively, there may be delays before symptoms change. Some research has 
identified that concussion symptoms may have a delayed onset (2), and accordingly a 
reduction in symptoms could also be delayed. Therefore, future work is encouraged to 
investigate the prolonged effects of LoRETA neurofeedback and HRV biofeedback.  
Considering this experiment as a whole, along with two illustrative case reports, it is clear 
that our intervention of combined LoRETA neurofeedback and heart rate variability 
biofeedback is promising for some individuals. We have not focused on identifying the 
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characteristics of individuals that respond, though that is an important avenue for future 
research. 
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6 Conclusions 
In conclusion, interventions that combine LoRETA neurofeedback and HRV biofeedback 
are beneficial for some individuals with PPCS. It reduces EEG deviations, reduces 
driving simulation reaction time and lane deviation, and reduces symptoms in some 
individuals. The effectiveness of this intervention appears to differ between individuals, 
and further research is necessary to investigate whether it is possible to identify which 
individuals are likely to respond. It is well-understood that certain concussion symptoms 
are associated with prolonged duration of symptoms after a concussion (99), and so it 
may be that there are commonalities between individuals that respond to this type of 
intervention. Furthermore, studies that include longer follow-up times and larger 
populations should be performed to clarify and confirm the trends that have been 
identified in this study.  
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Appendix B: Generalized Anxiety Disorder Scale 
 
  
The Generalized Anxiety Disorder 7-Item Scale 
 
Over the last 2 weeks, how often have you been bothered by the 
following problems? 
 
Not 
at all 
Several 
Days 
More 
than half 
the days 
Nearly 
every 
day 
1. Feeling nervous, anxious, or on edge 
 
0 1 2 3 
2. Not being able to stop or control worrying 
 
0 1 2 3 
3. Worrying too much about different things 
 
0 1 2 3 
4. Trouble relaxing 
 
0 1 2 3 
5. Being so restless that it is hard to sit still 
 
0 1 2 3 
6. Becoming easily annoyed or irritable 
 
0 1 2 3 
7. Feeling afraid as if something awful might happen 
 
0 1 2 3 
 
 
Total Score:     =  Add Columns  _______+ _______+_______ 
 
 
If you checked off any problems, how difficult have these problems made it for you to do your 
work, take care of things at home, or get along with other people? 
 
Not at all  Somewhat difficult  Very difficult  Extremely Difficult 
 
______        ______           ______         ______ 
 
 
 
Interpreting the Score: 
 
Total Score Interpretation  
≥ 10 Possible diagnosis of GAD; confirm by 
further evaluation  
5 Mild Anxiety 
10 Moderate anxiety 
15 Severe anxiety  
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Appendix C: Rivermead Post-Concussion Symptoms Questionnaire 
  
 
   
The Rivermead Post-Concussion Symptoms Questionnaire* 
 
 
After a head injury or accident some people experience symptoms which can cause worry or 
nuisance.  We would like to know if you now suffer from any of the symptoms given below.  
As many of these symptoms occur normally, we would like you to compare yourself now with 
before the accident.  For each one, please circle the number closest to your answer. 
 
0 =   Not experienced at all 
1 =   No more of a problem 
2 =   A mild problem 
3 =   A moderate problem 
4 =   A severe problem 
 
 
Compared with before the accident, do you now (i.e., over the last 24 hours) suffer from: 
 
Headaches.................................................. 0 1 2 3 4 
Feelings of Dizziness ................................. 0 1 2 3 4 
Nausea and/or Vomiting ........................... 0 1 2 3 4 
Noise Sensitivity, 
 easily upset by loud noise ................ 0 1 2 3 4 
Sleep Disturbance ...................................... 0 1 2 3 4 
Fatigue, tiring more easily ......................... 0 1 2 3 4 
Being Irritable, easily angered .................. 0 1 2 3 4 
Feeling Depressed or Tearful .................... 0 1 2 3 4 
Feeling Frustrated or Impatient ................ 0 1 2 3 4 
Forgetfulness, poor memory ..................... 0 1 2 3 4 
Poor Concentration .................................... 0 1 2 3 4 
Taking Longer to Think .............................. 0 1 2 3 4 
Blurred Vision ............................................. 0 1 2 3 4 
Light Sensitivity,  
 Easily upset by bright light ................ 0 1 2 3 4 
Double Vision ............................................. 0 1 2 3 4 
Restlessness .............................................. 0 1 2 3 4 
 
 
Are you experiencing any other difficulties? 
 
1. _______________________________  0 1 2 3 4 
 
2. _______________________________  0 1 2 3 4 
 
 
 
*King, N., Crawford, S., Wenden, F., Moss, N., and Wade, D. (1995) J. Neurology 242: 587-592 
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